Clarity Pharmaceuticals Secures Large-Scale Copper-64 Supply Deal with Theragenics
Event summary
- Clarity Pharmaceuticals signed a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics, effective March 25, 2026.
- Theragenics' 134,000 square foot facility with 14 cyclotrons near Atlanta can produce ~100Ci (3.7 TBq) of copper-64 daily, supporting ~2,000 patient doses per cyclotron.
- The deal complements Clarity's existing supply agreements with SpectronRx and Nusano, strengthening its US manufacturing network ahead of the anticipated commercial launch of 64Cu-SAR-bisPSMA.
- Copper-64's 12.7-hour half-life enables a 48-hour shelf life for 64Cu-SAR-bisPSMA, addressing supply chain inefficiencies of shorter-lived isotopes.
The big picture
This deal underscores Clarity's strategic pivot toward securing robust manufacturing infrastructure ahead of potential FDA approvals. The partnership with Theragenics—combined with existing agreements—positions Clarity to capitalize on the growing demand for next-generation radiodiagnostics in oncology. The industry is shifting toward longer-lived isotopes to reduce supply chain costs, and Clarity's copper-64 platform could set a new standard for scalability and profitability in radiopharmaceuticals.
What we're watching
- Regulatory Milestones
- The pace at which Clarity's Phase III trials (AMPLIFY and CLARIFY) conclude and secure FDA approval will dictate the timeline for commercial launch.
- Supply Chain Scalability
- Whether Clarity's multi-partner manufacturing network can sustain commercial-scale demand across multiple oncology indications.
- Market Differentiation
- How copper-64's longer half-life and Theragenics' expertise will position 64Cu-SAR-bisPSMA against competitors using gallium-68 or fluorine-18.
Related topics